GlassScriptPhysician profile
David R Collins
NPI 1699777326
$3,229.07
in general payments reported to CMS, 2019-2025
23 companies · $533 in 2025
The $533 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $216 · 2021: $155 · 2022: $361 · 2023: $490 · 2024: $805 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $401.70 | 2019-2023 | |
| Corium, LLC | $391.22 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $373.25 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $368.65 | 2023-2024 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $230.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $211.58 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $177.59 | 2019-2023 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $164.99 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Astrazeneca Pharmaceuticals LP | $147.89 | 2023-2025 | Fasenra, Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $112.25 | 2025 | Jornay Pm |
| Kaleo, INC. | $107.18 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.16 | 2019-2021 | |
| Cranial Technologies, INC | $71.71 | 2019-2022 | |
| Sanofi Pasteur INC. | $71.02 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $68.00 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $60.41 | 2025 | Id Now Instrument |
| Novartis Pharmaceuticals Corporation | $45.31 | 2019 | |
| Sobi, INC | $36.07 | 2019-2020 | |
| Adlon Therapeutics L.P. | $31.59 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $20.83 | 2024 | Ycanth |
| Ars Pharmaceuticals Operations, INC. | $17.38 | 2025 | Neffy |
| Vertical Pharmaceuticals, LLC | $15.12 | 2024 | Relexxii |
| Phadia US INC. | $13.62 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.